| Value | ₹4,018 Cr |
|---|
BSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,300.00
- Market cap
- ₹64,912 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 36.1×Sector 46.1×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Glenmark Pharmaceuticals Other Announcement
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched Adapalene Gel USP, 0.1% (OTC) in new pump packs in the USA, expanding its dermatology portfolio.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Other results update announcements
All →Vaibhav Global Results Update
Vaibhav Global reported H1 & Q2 FY27 results via press release, with Q2 revenue up 7.0% to ₹938.4 crore and EBITDA of ₹76.2 crore. The release covers platform migration effects and segment performance.
InfoBeans Technologies Results Update
InfoBeans Technologies reported Q2 and H1 FY27 results, with H1 revenue up 30% to ₹322.6 crore and PAT up 22% to ₹47.9 crore. Management highlighted growth momentum, new clients and EBITDA gains.
OnEMI Technology Solutions Results Update
Kissht reported Q2FY27 PAT of ₹125 Crore, doubling year-on-year, with AUM up 68% to ₹9,317 Crore. Press release accompanies unaudited Q2 and H1 FY27 results.
GMR Airports Results Update
GMR Airports reported Q2FY27 total income up 12% YoY to INR 4,188 Crs and PAT of INR 65 Crs. The filing is a press release accompanying the un-audited quarterly results.
MosChip Technologies Results Update
MosChip's Q2 FY27 press release showed revenue of ₹119.08 Crore and an EBITDA loss of ₹18.82 Crore. Cost escalations on a turnkey ASIC project drove weaker profit.
Zensar Technologies Results Update
Zensar Technologies reported 4.1% sequential constant currency revenue growth to $166.2M for Q2FY27, with EBITDA margin at 15.8%. The release is a press release accompanying the quarterly results presentation.